India, Aug. 18 -- Kura Oncology, Inc. (KURA) recently reported second-quarter 2026 financial results, highlighted by strong commercial momentum for KOMZIFTI (ziftomenib) and continued progress across its AML and solid tumor pipeline.
KOMZIFTI (ziftomenib) is Kura Oncology's FDA-approved, once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML).
The U.S. FDA granted full approval to KOMZIFTI on November 13, 2025, for this indication.
KOMZIFTI (ziftomenib) generated $9.1 million in net product revenue in Q2 2026, up 57% compared with no net product revenue in Q2 2025.
The company recorded approximately 115 new patient starts, a 35% sequential increase, while total prescriptions excee...